Justin R Halman1, Ki-Taek Kim2, So-Jung Gwak2, Richard Pace2, M Brittany Johnson3, Morgan R Chandler1, Lauren Rackley1, Mathias Viard4, Ian Marriott3, Jeoung Soo Lee5, Kirill A Afonin6. 1. Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC, USA. 2. Drug Design, Development, and Delivery (4D) Laboratory, Department of Bioengineering, Clemson University, Clemson, SC, USA. 3. Department of Biological Sciences, University of North Carolina at Charlotte, 9201 University City Boulevard, Charlotte, NC, USA. 4. Cancer and Inflammation Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA. 5. Drug Design, Development, and Delivery (4D) Laboratory, Department of Bioengineering, Clemson University, Clemson, SC, USA. Electronic address: ljspia@clemson.edu. 6. Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC, USA. Electronic address: kafonin@uncc.edu.
Abstract
Programmable nucleic acid nanoparticles (NANPs) provide controlled coordination of therapeutic nucleic acids (TNAs) and other biological functionalities. Beyond multivalence, recent reports demonstrate that NANP technology can also elicit a specific immune response, adding another layer of customizability to this innovative approach. While the delivery of nucleic acids remains a challenge, new carriers are introduced and tested continuously. Polymeric platforms have proven to be efficient in shielding nucleic acid cargos from nuclease degradation while promoting their delivery and intracellular release. Here, we venture beyond the delivery of conventional TNAs and combine the stable cationic poly-(lactide-co-glycolide)-graft-polyethylenimine with functionalized NANPs. Furthermore, we compare several representative NANPs to assess how their overall structures influence their delivery with the same carrier. An extensive study of various formulations both in vitro and in vivo reveals differences in their immunostimulatory activity, gene silencing efficiency, and biodistribution, with fibrous NANPs advancing for TNA delivery.
Programmable nucleic acid nanoparticles (n class="Gene">NANPs) provide controlled coordination of therapeutic nucleic acids (n class="Chemical">TNAs) and other biological functionalities. Beyond multivalence, recent reports demonstrate that NANP technology can also elicit a specific immune response, adding another layer of customizability to this innovative approach. While the delivery of nucleic acids remains a challenge, new carriers are introduced and tested continuously. Polymeric platforms have proven to be efficient in shielding nucleic acid cargos from nuclease degradation while promoting their delivery and intracellular release. Here, we venture beyond the delivery of conventional TNAs and combine the stable cationic poly-(lactide-co-glycolide)-graft-polyethylenimine with functionalized NANPs. Furthermore, we compare several representative NANPs to assess how their overall structures influence their delivery with the same carrier. An extensive study of various formulations both in vitro and in vivo reveals differences in their immunostimulatory activity, gene silencing efficiency, and biodistribution, with fibrous NANPs advancing for TNA delivery.
Authors: My N Bui; M Brittany Johnson; Mathias Viard; Emily Satterwhite; Angelica N Martins; Zhihai Li; Ian Marriott; Kirill A Afonin; Emil F Khisamutdinov Journal: Nanomedicine Date: 2017-01-04 Impact factor: 5.307
Authors: David Adams; Alejandra Gonzalez-Duarte; William D O'Riordan; Chih-Chao Yang; Mitsuharu Ueda; Arnt V Kristen; Ivailo Tournev; Hartmut H Schmidt; Teresa Coelho; John L Berk; Kon-Ping Lin; Giuseppe Vita; Shahram Attarian; Violaine Planté-Bordeneuve; Michelle M Mezei; Josep M Campistol; Juan Buades; Thomas H Brannagan; Byoung J Kim; Jeeyoung Oh; Yesim Parman; Yoshiki Sekijima; Philip N Hawkins; Scott D Solomon; Michael Polydefkis; Peter J Dyck; Pritesh J Gandhi; Sunita Goyal; Jihong Chen; Andrew L Strahs; Saraswathy V Nochur; Marianne T Sweetser; Pushkal P Garg; Akshay K Vaishnaw; Jared A Gollob; Ole B Suhr Journal: N Engl J Med Date: 2018-07-05 Impact factor: 91.245
Authors: O Boussif; F Lezoualc'h; M A Zanta; M D Mergny; D Scherman; B Demeneix; J P Behr Journal: Proc Natl Acad Sci U S A Date: 1995-08-01 Impact factor: 11.205
Authors: Kirill A Afonin; Mathias Viard; Angelica N Martins; Stephen J Lockett; Anna E Maciag; Eric O Freed; Eliahu Heldman; Luc Jaeger; Robert Blumenthal; Bruce A Shapiro Journal: Nat Nanotechnol Date: 2013-03-31 Impact factor: 39.213
Authors: Kirill A Afonin; Wojciech K Kasprzak; Eckart Bindewald; Maria Kireeva; Mathias Viard; Mikhail Kashlev; Bruce A Shapiro Journal: Acc Chem Res Date: 2014-04-23 Impact factor: 22.384
Authors: Allison N Tran; Morgan Chandler; Justin Halman; Damian Beasock; Adam Fessler; Riley Q McKeough; Phuong Anh Lam; Daniel P Furr; Jian Wang; Edward Cedrone; Marina A Dobrovolskaia; Nikolay V Dokholyan; Susan R Trammell; Kirill A Afonin Journal: Small Date: 2022-02-06 Impact factor: 13.281
Authors: Morgan Brittany Johnson; Justin R Halman; Daniel K Miller; Joseph S Cooper; Emil F Khisamutdinov; Ian Marriott; Kirill A Afonin Journal: Nucleic Acids Res Date: 2020-11-18 Impact factor: 16.971
Authors: Renata F Saito; Maria Cristina Rangel; Justin R Halman; Morgan Chandler; Luciana Nogueira de Sousa Andrade; Silvina Odete-Bustos; Tatiane Katsue Furuya; Alexis Germán Murillo Carrasco; Adriano B Chaves-Filho; Marcos Y Yoshinaga; Sayuri Miyamoto; Kirill A Afonin; Roger Chammas Journal: Nanomedicine Date: 2021-06-24 Impact factor: 6.096